The MDS Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Gilead Oncology,Geron, Syros Pharmaceuticals and Curis Inc.. This supporter has no influence over the production of the content.

Latest Videos The MDS Sessions Conferences Features Podcasts Topics Expert Editorial Board

Welcome to The Myelodysplastic Syndromes (MDS) Channel

Explore all things new and exciting in MDS, with exclusive insights, must-know news, and unique expert perspectives, courtesy of The MDS Channel.

Much research is underway to address the paucity of available options in MDS and many new agents, targets, and treatment approaches are in development or under investigation, such as novel HMA-based combinations, immunotherapies, and other newer agents. With the support of a world-leading Editorial Board, VJHemOnc brings you informative interviews, roundtable discussions, feature articles, and podcasts; a one-stop source for the key MDS news!

Conferences

BSH 2023
ASH 2022
SOHO 2022
EHA 2022
ASCO 2022
Tandem Meetings 2022
2:11
Unmet needs in bone marrow failure syndromes & myeloid malignancies: characterization & novel agents
Inderjeet Dokal • 23 Apr 2023
1:35
Challenges with diagnosing MDS and future outlooks
Manoj Raghavan • 23 Apr 2023
3:31
Promising treatment options emerging for higher-risk MDS & the value of clinical trials
Pramila Krishnamurthy • 24 Apr 2023
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
View All Videos
1:12
CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS
Jayastu Senapati • 11 Dec 2022
4:00
Real-world data on the efficacy of luspatercept in LR-MDS
Rami Komrokji • 19 Dec 2022
0:56
The promise of luspatercept for the treatment of lower-risk MDS
Valeria Santini • 12 Dec 2022
4:21
Evaluating luspatercept in combination with ESAs for the treatment of anemia in LR-MDS
Rami Komrokji • 19 Dec 2022
View All Videos
1:44
Exciting advancements in the MDS space
Ryotaro Nakamura • 28 Sep 2022
2:47
An insight into the biology of CHIP and CCUS and their role in hematological malignancies
Amir Fathi • 22 Sep 2022
2:10
Using the innate immune system to treat MDS & the value of novel immunotherapies
David Sallman • 3 Oct 2022
1:59
The role of inflammatory signaling pathways in lower-risk MDS
David Sallman • 3 Oct 2022
View All Videos
1:42
Unmet needs in high-risk MDS and ongoing trials in the field
Thomas Cluzeau • 12 Jun 2022
1:30
Optimizing transfusion support for patients with MDS
Shuh Ying Tan • 29 Jun 2022
3:47
The role of immunotherapy in the AML treatment landscape
Thomas Cluzeau • 12 Jun 2022
1:20
The current standard of care for patients with lower-risk MDS
Shuh Ying Tan • 29 Jun 2022
View All Videos
1:59
Mutational burden at relapse following exposure to high dose melphalan in multiple myeloma
Paul Richardson • 5 Jun 2022
View All Videos
1:27
Challenges in CAR-T therapy for myeloid malignancies
Bhagirathbhai Dholaria • 24 Apr 2022
5:47
Use of belimumab for prophylaxis of chronic GvHD
Iskra Pusic • 24 Apr 2022
1:40
Outcomes of alloHSCT in TP53-mutated AML and MDS
Muhammad Umair Mushtaq • 25 Apr 2022
2:31
Sorafenib or venetoclax in fractionated busulfan conditioning regimen for AML & MDS
Uday Popat • 23 Apr 2022
View All Videos

Topics

Immuno-Oncology
Trial Updates
Treatment
Transplantation
Disease Biology
Diagnosis
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023
3:31
Promising treatment options emerging for higher-risk MDS & the value of clinical trials
Pramila Krishnamurthy • 24 Apr 2023
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
1:38
The role and targeting of immune dysregulation in MDS
Uwe Platzbecker • 11 May 2023
View All Videos
1:12
ABNL MARRO: ongoing clinical study investigating MDS/MPN overlap syndromes
Michael Savona • 5 May 2023
1:02
TakeAim Leukemia: positive interim results regarding the efficacy of emavusertib in HR-MDS and AML
Uwe Platzbecker • 11 May 2023
3:35
Real-world validation of the value of the IPSS-M for prognostication in patients with MDS
Matteo Della Porta • 27 May 2023
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
View All Videos
6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023
3:01
Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis
Klaus Metzeler • 5 May 2023
1:12
ABNL MARRO: ongoing clinical study investigating MDS/MPN overlap syndromes
Michael Savona • 5 May 2023
View All Videos
6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023
3:35
Real-world validation of the value of the IPSS-M for prognostication in patients with MDS
Matteo Della Porta • 27 May 2023
2:11
Unmet needs in bone marrow failure syndromes & myeloid malignancies: characterization & novel agents
Inderjeet Dokal • 23 Apr 2023
View All Videos
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023
3:01
Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis
Klaus Metzeler • 5 May 2023
1:41
Pursuing combination therapies to overcome single-agent HMA failure in patients with MDS
Aditi Shastri • 4 May 2023
4:16
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman • 5 May 2023
View All Videos
6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
3:01
Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis
Klaus Metzeler • 5 May 2023
4:16
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman • 5 May 2023
3:35
Real-world validation of the value of the IPSS-M for prognostication in patients with MDS
Matteo Della Porta • 27 May 2023
View All Videos

The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Gilead Oncology,Geron, Syros Pharmaceuticals and Curis Inc..

This supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The MDS Channel, please contact us.

VJHemOnc is pleased to be media partners with the MDS Foundation, visit their website to learn more.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals